Abhimanyu Garg, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1871562355
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,740 of the $27,416 with a category attached, or 72.0%. 5 manufacturers reported payments, led by Regeneron at 45.6% of the total. Reporting peaked in 2023 at $8,721 and has fallen 98.4% since, to $137 in 2025.
Across 37 payments — averaging $740.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$12K
- Amryt Pharma Holdings Ltd$8K
- Aegerion Pharmaceuticals, Inc.$4K
- Chiesi USA, Inc.$3K
- Abbott$137
Across 611 payments — averaging $1466.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$390K
- Chiesi USA, Inc.$225K
- Amryt Pharma Holdings Ltd$172K
- Akcea Therapeutics, Inc.$61K
- Aegerion Pharmaceuticals, Inc.$48K
What the payments were for
- Consulting fees$19,74072%
- Speaking & faculty fees$3,49213%
- Travel & lodging$3,54613%
- Food & beverage$6382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 21 | $12,490 |
| Amryt Pharma Holdings Ltd | 5 | $7,609 |
| Aegerion Pharmaceuticals, Inc. | 9 | $3,689 |
| Chiesi USA, Inc. | 1 | $3,492 |
| Abbott | 1 | $137 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYALEPT$14,492
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$137
How this compares
$27,416 in reported general payments places this provider in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyaleptMetreleptin | 11 | $1,837,443 |
| Praluent PenAlirocumab | 34 | $19,085 |
| Repatha SureclickEvolocumab | 23 | $11,998 |
| JardianceEmpagliflozin | 11 | $7,516 |
| Omega-3 Acid Ethyl Esters | 31 | $2,385 |
| Levothyroxine Sodium | 21 | $456 |
| Ezetimibe | 31 | $363 |
| Atorvastatin Calcium | 17 | $175 |
| Rosuvastatin Calcium | 19 | $116 |
| Pravastatin Sodium | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Chiesi USA, Inc.Myalept | $3,492 | $1,837,44311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Pablo MoraDallas$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Ildiko LingvayDallas$711K
- Rajiv DattatreyaDallas$437K
- Jaime AlmandozDallas$334K
- Luigi MeneghiniDallas$136K
- Oksana HamidiDallas$106K
- Lance SloanLufkin$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.